Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We report the outcome for children and young people with Down syndrome-associated acute lymphoblastic leukaemia (DS-ALL) treated on a contemporary protocol. Compared with non-DS ALL, patients with DS-ALL had an inferior event-free survival (65·6% vs. 87·7% at 5 years; P < 0·00005) and overall survival (70·0% vs. 92·2%; P < 0·00005). Excess treatment-related mortality - was primarily responsible for the worse outcomes for DS-ALL (21·6% at 5 years, vs. 3·3%, P < 0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.

Original publication

DOI

10.1111/bjh.12739

Type

Journal article

Journal

Br J Haematol

Publication Date

05/2014

Volume

165

Pages

552 - 555

Keywords

Down syndrome, lymphoblastic leukaemia, treatment, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Chromosome Aberrations, Disease-Free Survival, Down Syndrome, Female, Follow-Up Studies, Gastrointestinal Hemorrhage, Genetic Predisposition to Disease, Humans, Infant, Infection, Male, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Risk Assessment, Treatment Outcome, Young Adult